Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	18883-66-4
Formula :	C₈H₁₅N₃O₇
M.W :	265.22
SMILES Code :	O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](NC(N(C)N=O)=O)[C@H]1O
Synonyms :	NSC-85998; SZN; SZC
InChI Key :	ZSJLQEPLLKMAKR-GKHCUFPYSA-N
Pubchem ID :	29327

GHS Pictogram:
Signal Word:	Danger
Hazard Statements:	H350
Precautionary Statements:	P201-P308+P313
Class:	6.1
UN#:	2811
Packing Group:	Ⅲ

Rats	Streptozotocin-induced type 1 diabetes model	Intraperitoneal injection	50 mg/kg	Single injection	The study aimed to investigate the therapeutic effects of hDPSCs transplantation on parotid gland injury in a rat model of STZ-induced type 1 diabetes. Results showed that hDPSCs transplantation decreased blood glucose, improved parotid gland weight and salivary flow rate, reduced oxidative stress, and promoted parotid cell regeneration.	PMC8591949
C57BL/6J mice	Streptozotocin-induced diabetes model	Intraperitoneal injection	Single high dose 150 mg/kg or multiple low doses 50 mg/kg	Single high dose administered once, multiple low doses administered over 5 consecutive days	To study the effects of streptozotocin on pancreatic β-cells and observe the progression of hyperglycemia and diabetes	PMC9464185
Sprague-Dawley rats	Streptozotocin-induced diabetic rat model	Intraperitoneal injection	60 mg/kg	Single injection	To investigate the effect of glycemic variability on peripheral nerve damage in streptozotocin-induced diabetic rats. The results suggest that glucose control itself is more important than glucose fluctuation in preventing peripheral nerve damage.	PMC8831810
Mice	1/3 NT + STZ-induced diabetic nephropathy model	Intraperitoneal injection	75 mg/kg and 100 mg/kg	Once a week for 7 days	To evaluate the protective effect of EtCE-EA on diabetic nephropathy, results showed that EtCE-EA effectively improved renal function indicators and reduced renal damage.	PMC10002342
Mice	3xTg-AD mice	Intracerebroventricular injection	3.0 mg/kg	Single injection, lasting 3-6 weeks	To investigate the effects of STZ on cognitive function and Alzheimer-like brain abnormalities in 3xTg-AD mice. Results showed that STZ exacerbated impairment of short-term and spatial reference memory, increased tau hyperphosphorylation and neuroinflammation, disturbed brain insulin signaling, and decreased synaptic plasticity and amyloid β peptides in the brain.	PMC3948211

{[proInfo.proName]}

CAS No.: 18883-66-4

{[proInfo.proName]}

CAS No.: 18883-66-4

Product Citations

Alternative Products

Product Details of Streptozotocin

Safety of Streptozotocin

Related Pathways of Streptozotocin

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT01362530	Chemotherapy Induced Nausea an... More >>d Vomiting Less <<	Phase 3	Completed	-	-
NCT01362530	-		Completed	-	-
NCT00003543	Colorectal Cancer	Phase 1	Completed	-	United States, New York ... More >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Less <<
NCT01709123	Diabetes Mellitus, Type 1	Not Applicable	Unknown	September 2013	United States, Louisiana ... More >> Louisiana State University Health Sciences Center in Shreveport Recruiting Shreveport, Louisiana, United States, 71130 Contact: Sushil K Jain, Ph.D. 318-675-6086 sjain@lsuhsc.edu Sub-Investigator: Robert McVie, M.D. Sub-Investigator: Tommie Stapleton, RN, CCRC Sub-Investigator: Cynthia Brewer, RN Sub-Investigator: John Rowell, RN, MSN Sub-Investigator: Henry R McKnight, RPH Sub-Investigator: Pat F Bass, M.D. Sub-Investigator: Shikha Mane, M.D. Sub-Investigator: David Micinski, BS Sub-Investigator: Neslihan Gungor, M.D. Less <<
NCT03758014	GBM	Phase 2 Phase 3	Recruiting	April 30, 2021	China, Beijing ... More >> Beijing Tiantan Hospital, Capital Medical University Recruiting Beijing, Beijing, China Contact: Wenbin Li Less <<
NCT00448136	Neoplasms	Phase 2	Completed	-	France ... More >> Angers, France, 49933 Bordeaux, France, 33075 Boulogne Billancourt, France, 92104 Caen, France, 14033 Chambray Les Tours, France, 37171 Clichy, France, 92118 Creteil, France, 94010 Dijon, France, 21079 Lille, France, 59020 Lyon, France, 69437 Marseille, France, 13273 Marseille, France, 13285 Marseille, France, 13385 Montpellier, France, 34298 Nantes, France, 44093 Nice, France, 06189 Paris, France, 75571 Paris, France, 75651 Paris, France, 75908 Paris, France, 75970 Poitiers, France, 86021 Reims, France, 51092 Rouen, France, 76031 Saint Brieuc, France, 22015 Strasbourg, France, 67091 Toulouse, France, 31059 Villejuif, France, 94805 Less <<
NCT03217097	Neuroendocrine Tumors	Phase 4	Not yet recruiting	October 2021	France ... More >> Hôpital Sud - CHU Amiens Not yet recruiting Amiens, France, 80054 Contact: Vincent HAUTEFEUILLE, MD Principal Investigator: Vincent HAUTEFEUILLE, MD CHU d'Angers Not yet recruiting Angers, France, 49933 Contact: Sandrine LABOUREAU, MD Principal Investigator: Sandrine LABOUREAU, MD Hôpital Beaujon - APHP Not yet recruiting Clichy, France, 92118 Contact: Olivia HENTIC, MD Principal Investigator: Olivia HENTIC, MD Hôpital François Mitterrand - CHU Dijon Bourgogne Not yet recruiting Dijon, France, 21000 Contact: Côme LEPAGE, MD Principal Investigator: Côme LEPAGE, MD Hôpital André Michalon - CHU Grenoble Alpes Not yet recruiting La Tronche, France, 38700 Contact: Victoire GRANGER, MD Principal Investigator: Victoire GRANGER, MD Centre Oscar Lambret Not yet recruiting Lille, France, 59020 Contact: Eric DANSIN, MD Principal Investigator: Eric DANSIN, MD Hôpital Claude Hurriet - CHRU Lille Not yet recruiting Lille, France, 59037 Contact: Christine DO CAO, MD Principal Investigator: Christine DO CAO, MD Hôpital Edouard Herriot - Hospices Civils de Lyon Not yet recruiting Lyon, France, 69003 Contact: Thomas WALTER, MD Principal Investigator: Catherine LOMBARD BOHAS, MD Sub-Investigator: Thomas WALTER, MD Hôpital Privé Jean Mermoz Not yet recruiting Lyon, France, 69008 Contact: Jérôme DESRAMES, MD Principal Investigator: Jérôme DESRAMES, MD Centre Léon Bérard Not yet recruiting Lyon, France, 69373 Contact: Matthieu SARABI, MD Principal Investigator: Matthieu SARABI, MD Institut Paoli Calmettes Not yet recruiting Marseille, France, 13009 Contact: Patricia NICCOLI, MD Principal Investigator: Patricia NICCOLI, MD Hôpital Saint Eloi - CHU Montpellier Not yet recruiting Montpellier, France, 34090 Contact: Eric ASSENAT, MD Principal Investigator: Eric ASSENAT, MD Hôpital Saint Louis - APHP Not yet recruiting Paris, France, 75010 Contact: Thomas APARICIO, MD Principal Investigator: Thomas APARICIO, MD Hôpital Cochin - APHP Not yet recruiting Paris, France, 75014 Contact: Romain CORIAT, MD Principal Investigator: Romain CORIAT, MD CH Annecy Genevois Not yet recruiting Pringy, France, 74374 Contact: Mathieu BACONNIER, MD Principal Investigator: Mathieu BACONNIER, MD Hôpital Robert Debré - CHU Reims Not yet recruiting Reims, France, 51092 Contact: Guillaume CADIOT, MD Principal Investigator: Guillaume CADIOT, MD Hôpital Nord - CHU Saint Etienne Not yet recruiting Saint-Priest-en-Jarez, France, 42270 Contact: Nicolas WILLIET, MD Principal Investigator: Nicolas WILLIET, MD Institut de Cancérologie de la Loire Not yet recruiting Saint-Priest-en-Jarez, France, 42270 Contact: Léa SABAN-ROCHE, MD Principal Investigator: Léa SABAN-ROCHE, MD Hôpital Rangueil - CHU Toulouse Not yet recruiting Toulouse, France, 31059 Contact: Rosine GUIMBAUD, MD Principal Investigator: Rosine GUIMBAUD, MD Hôpital Trousseau - CHU Tours Not yet recruiting Tours, France, 37044 Contact: Thierry LECOMTE, MD Principal Investigator: Thierry LECOMTE, MD Institut Gustave Roussy Not yet recruiting Villejuif, France, 94805 Contact: Eric BAUDIN, MD Principal Investigator: Eric BAUDIN, MD Less <<
NCT00633763	-		Completed	-	United States, California ... More >> University of California Irvine Medical Center Orange, California, United States, 92868 Less <<
NCT02246127	Neuroendocrine Tumors	Phase 3	Recruiting	June 2020	-
NCT00094497	Carcinoma, Adrenal Cortical	Phase 3	Completed	-	United States, Maryland ... More >> National Cancer Institute - Center for Cancer Research Bethesda, Maryland, United States United States, Michigan University of Michigan, Department of Internal Medicine Ann Arbor, Michigan, United States, 48109 Australia Royal Adelaide Hospital Adelaide, Australia, SA 5000 Austria University of Graz Graz, Austria, 8036 France Clinique Marc Linquette Lille, France Centre Leon Berard Lyon, France Hospital de Marseille la timone Marseille, France, 13385 Cochin Hospital Paris, France, 75679 Hospital Bordeaux haut leveque Pessac, France, 33600 Institut Gustave Roussy Villejuif, France, 94805 Germany Charité-University, Dept. of Endocrinology; Campus Benjamin Franklin Berlin, Germany Charité-Universitätsmedizin Berlin - Campus Mitte Berlin, Germany Dept. of Medicine III Dresden, Germany University of Duesseldorf, Dept. of Endocrrinology Duesseldorf, Germany, 40001 Zentrum für Innere Medizin - Endokrinologie des Universitätsklinikum Essen Essen, Germany Endokrinologie Medizinische Hochschule Hannover Hannover, Germany Otto-von-Guericke University; Dept. of Endocrinology Magdeburg, Germany, 39120 Dept of Medicine I Mainz, Germany University of Munich, Dept. of Internal Medicine (Innenstadt) Munich, Germany, 80336 University of Wuerzburg - Dept. of Medicine Wuerzburg, Germany, 97080 Italy University of Turin, Dept of Internal Medicine Orbassano, Italy, 10043 Clinica Endocrinologica, Università di Padova, Azienda Ospedaliera di Padova Padova, Italy Netherlands Vrije Universiteit Medisch Centrum Amsterdam, Netherlands, 1007 Academisch Medisch Centrum; Dept. of Endocrinology Amsterdam, Netherlands, 1105 AZ Maxima Medisch Centrum; Dept. of Internal Medicine Eindhoven, Netherlands, 5631 BM University Hospital Groningen; Dept. of Internal Medine Groningen, Netherlands, 9700 Leiden University Medical Center Leiden, Netherlands Sweden Department of Oncology, Sahlgrenska University Hospital Gothenburg, Sweden Department of Oncology, Linköping University Hospital Linköping, Sweden Department of Medicine, The Jubileum Institute, Lund University Lund, Sweden Dept of Surgery, Karolinska Hospital, Stockholm Stockholm, Sweden Uppsala University Hospital - Dept of Medical Sciences Uppsala, Sweden, 751 85 Less <<
NCT00094497	-		Completed	-	-
NCT00001165	Islet Cell Adenoma ... More >> Neoplasm Metastasis Zollinger Ellison Syndrome Less <<	Phase 2	Completed	-	United States, Maryland ... More >> National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Bethesda, Maryland, United States, 20892 Less <<
NCT03351296	Pancreatic Cancer	Phase 2	Not yet recruiting	June 2023	France ... More >> Gustave Roussy Not yet recruiting Villejuif, Val De Marne, France, 94805 Contact: Michel Ducreux, MD, PhD 0142116017 ext +33 michel.ducreux@gustaveroussy.fr Contact: Dune Lemettre 0142116643 ext +33 dune.lemettre@gustaveroussy.fr Less <<
NCT00602082	Gastrointestinal Carcinoid Tum... More >>or Islet Cell Tumor Less <<	Phase 2	Completed	-	United Kingdom ... More >> Basildon University Hospital Basildon, England, United Kingdom, SS16 5NL Addenbrooke's Hospital Cambridge, England, United Kingdom, CB2 2QQ Cookridge Hospital Leeds, England, United Kingdom, LS16 6QB Leicester Royal Infirmary Leicester, England, United Kingdom, LE1 5WW Aintree University Hospital Liverpool, England, United Kingdom, L9 7AL UCL Cancer Institute London, England, United Kingdom, NW3 2QG St. Thomas' Hospital London, England, United Kingdom, SE1 7EH Mid Kent Oncology Centre at Maidstone Hospital Maidstone, England, United Kingdom, ME16 9QQ Christie Hospital Manchester, England, United Kingdom, M20 4BX Clatterbridge Centre for Oncology Merseyside, England, United Kingdom, CH63 4JY Northern Centre for Cancer Treatment at Newcastle General Hospital Newcastle-Upon-Tyne, England, United Kingdom, NE4 6BE Oxford Radcliffe Hospital Oxford, England, United Kingdom, 0X3 9DU Royal Marsden - Surrey Sutton, England, United Kingdom, SM2 5PT Southend University Hospital NHS Foundation Trust Westcliff-On-Sea, England, United Kingdom, SS0 0RY Edinburgh Cancer Centre at Western General Hospital Edinburgh, Scotland, United Kingdom, EH4 2XU Beatson West of Scotland Cancer Centre Glasgow, Scotland, United Kingdom, G12 0YN Velindre Cancer Center at Velindre Hospital Cardiff, Wales, United Kingdom, CF14 2TL Less <<
NCT00609765	Pancreatic Cancer	Phase 2	Terminated(Development of new ... More >>chemotherapy standard of care for treatment rendered the trial obsolete.) Less <<	-	United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 Less <<
NCT00609765	-		Terminated(Development of new ... More >>chemotherapy standard of care for treatment rendered the trial obsolete.) Less <<	-	-
NCT00448136	-		Completed	-	-
NCT00004688	Anaplastic Astrocytoma ... More >> Anaplastic Oligodendroglioma Mixed Gliomas Glioblastoma Multiforme Recurrent Brain Tumor Less <<	Phase 2	Completed	-	-
NCT03612232	Adrenocortical Carcinoma	Phase 2	Not yet recruiting	June 2022	Germany ... More >> University Hospital Würzburg Not yet recruiting Würzburg, Germany, 97080 Contact: Matthias Kroiss, MD, PhD +4993120139740 Kroiss_M@ukw.de Contact: Martin Fassnacht, MD +4993120139200 Fassnacht_M@ukw.de Less <<

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed